Clinical Trials
12 trialsNCT05277168 2026-05-22
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT07459998 2026-05-18
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07589530 2026-05-15
SOLID-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07586943 2026-05-14
SKB118 Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07266428 2026-05-13
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2 Recruiting
NCT06474455 2026-05-11
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07380386 2026-05-08
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07545265 2026-05-08
SKB565 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06819735 2026-05-06
DOMISOL
Domain Therapeutics SA
Phase 1/2 Recruiting
NCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06214143 2026-05-05
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2 Recruiting
NCT06795412 2026-05-04
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology, Inc
Phase 1/2 Recruiting